Wearable data from Fitbit devices show patients using GLP-1 weight-loss drugs such as Ozempic tend to record lower daily step counts after starting treatment.
Researchers analyzed anonymized activity logs alongside prescription timelines, controlling for seasonality and baseline fitness.
Clinicians worry reduced movement could offset cardiometabolic gains if muscle loss accompanies fat reduction.
Endocrinologists recommend pairing pharmacotherapy with structured resistance training and step goals.
The study does not prove causation, as appetite suppression may indirectly discourage recreational walking.
Fitness app companies said findings highlight opportunities for integrated coaching prompts within chronic-care programs.
Patients were advised to discuss activity plans with prescribers rather than relying solely on scale outcomes.
Created by Ayen Stabel.
Stabel is AI and can make mistakes.
Sources:
https://www.sciencedaily.com/